Loading market data...
Sat, 15 Aug 2026
04:07:38 pm
Sat, 15 Aug 2026
04:07:38 pm
Rudransh Sangwan
Published at: August 10, 2026, 5:33 PM
Synopsis
Rakesh Jhunjhunwala portfolio 2026: Explore the latest holdings, top stocks, share prices, valuations and stock performance of Titan, Inventurus Knowledge Solutions, Metro Brands, Concord Biotech and Fortis Healthcare.
Rakesh Jhunjhunwala and Associates publicly holds 27 stocks with a portfolio value of more than ₹67,995 crore, based on the latest corporate shareholding data provided. The portfolio continues to have large positions in companies across jewellery, healthcare, technology, footwear retail and pharmaceuticals. Among the reported holdings, Titan Company is the largest position at ₹24,016.9 crore, followed by Inventurus Knowledge Solutions at ₹14,637.5 crore, Metro Brands at ₹3,786.9 crore, Concord Biotech at ₹3,575.8 crore and Fortis Healthcare at ₹2,868.5 crore. Together, these five holdings are worth about ₹48,885 crore based on the supplied data.
The five stocks also show very different recent market performances. Titan has gained 49.02% over the past year and 182.91% over five years, while Fortis Healthcare has delivered a 6.92% one-year return and 296.21% over five years. Concord Biotech has gained 11.50% in one month but remains down 13% over one year. Inventurus Knowledge Solutions has gained 6.51% over one year but has fallen 11.83% over five years, while Metro Brands has declined 14.59% over one year despite a 96.05% five-year return. The portfolio also saw changes during the June 2026 quarter, with the group trimming its Star Health holding by 14.1%, reducing Canara Bank by 0.1% and marginally reducing Baazar Style Retail by 0.1%.
The five stocks below represent some of the largest publicly reported positions in the portfolio. Titan accounts for the largest holding value at ₹24,016.9 crore, while Inventurus Knowledge Solutions has the highest reported ownership percentage at 49.3%. Metro Brands and Concord Biotech also have substantial ownership levels of 14.4% and 24.1%, respectively.
| Stock | Holding value | Shares held | Holding | Jun 2026 change |
|---|---|---|---|---|
| Titan Company | ₹24,016.9 crore | 4,71,84,470 | 5.3% | 0.0% |
| Inventurus Knowledge Solutions | ₹14,637.5 crore | 8,46,68,326 | 49.3% | 0.0% |
| Metro Brands | ₹3,786.9 crore | 3,91,53,600 | 14.4% | 0.0% |
| Concord Biotech | ₹3,575.8 crore | 2,51,99,240 | 24.1% | 0.0% |
| Fortis Healthcare | ₹2,868.5 crore | 3,03,50,152 | 4.0% | 0.0% |
Titan Company is the largest holding among the five stocks, with the Rakesh Jhunjhunwala and Associates portfolio holding 47,184,470 shares, equivalent to a 5.3% stake. The holding value is ₹24,016.9 crore. Titan operates across watches, jewellery and eyewear and is part of the Tata Group. The stock closed at ₹5,090 on August 10, 2026, giving the company a market capitalisation of ₹4,51,700 crore. Its P/E ratio stands at 77.4, while ROCE is 20.5% and ROE is 37.7%.
Loading chart...
| Metric | Titan Company |
|---|---|
| Share price | ₹5,090 |
| 52-week high | ₹5,122 |
| 52-week low | ₹3,303 |
| Market cap | ₹4,51,700 crore |
| P/E | 77.4 |
| Book value | ₹177 |
| Dividend yield | 0.29% |
| ROCE | 20.5% |
| ROE | 37.7% |
| Portfolio holding | 5.3% |
| Holding value | ₹24,016.9 crore |
Titan gained 3.02% on August 10 and was up 10.55% over one month. The stock has gained 49.02% over one year and 182.91% over five years.
| Period | Return |
|---|---|
| 1 day | +3.02% |
| 5 days | +4.41% |
| 1 month | +10.55% |
| 6 months | +19.55% |
| 1 year | +49.02% |
| 5 years | +182.91% |
Inventurus Knowledge Solutions is the second-largest holding by value, at ₹14,637.5 crore, with 84,668,326 shares held. The reported holding stands at 49.3%, unchanged in the June 2026 quarter. The company provides technology-enabled healthcare solutions through its care enablement platform, with a focus on healthcare organisations in the US, Canada and Australia. The stock closed at ₹1,729, giving it a market capitalisation of ₹29,685 crore. Its P/E is 38.9, while ROCE and ROE stand at 36.9% and 40.3%.
Loading chart...
| Metric | Inventurus Knowledge Solutions |
|---|---|
| Share price | ₹1,729 |
| 52-week high | ₹1,934 |
| 52-week low | ₹1,262 |
| Market cap | ₹29,685 crore |
| P/E | 38.9 |
| Book value | ₹131 |
| Dividend yield | 0.00% |
| ROCE | 36.9% |
| ROE | 40.3% |
| Portfolio holding | 49.3% |
| Holding value | ₹14,637.5 crore |
The stock fell 0.51% on August 10 and declined 8.55% over one month. It remained positive over six months and one year, with returns of 1.87% and 6.51%, respectively.
| Period | Return |
|---|---|
| 1 day | -0.51% |
| 5 days | -6.50% |
| 1 month | -8.55% |
| 6 months | +1.87% |
| 1 year | +6.51% |
| 5 years | -11.83% |
Metro Brands is the third-largest holding among these five stocks at ₹3,786.9 crore. The group holds 39,153,600 shares, representing 14.4% of the company. Metro Brands operates in the footwear and accessories retail segment and had 966 stores across 211 cities as of Q2 FY26, according to the supplied company information. The stock closed at ₹967 on August 10. It has a market capitalisation of ₹26,363 crore and trades at a P/E of 64.9.
Loading chart...
| Metric | Metro Brands |
|---|---|
| Share price | ₹967 |
| 52-week high | ₹1,340 |
| 52-week low | ₹883 |
| Market cap | ₹26,363 crore |
| P/E | 64.9 |
| Book value | ₹73.1 |
| Dividend yield | 0.31% |
| ROCE | 20.2% |
| ROE | 22.2% |
| Portfolio holding | 14.4% |
| Holding value | ₹3,786.9 crore |
Metro Brands declined 0.54% on August 10 and was down 8.58% over one month. The stock also fell 14.59% over one year, although its five-year return remained positive at 96.05%.
| Period | Return |
|---|---|
| 1 day | -0.54% |
| 5 days | -6.69% |
| 1 month | -8.58% |
| 6 months | -7.96% |
| 1 year | -14.59% |
| 5 years | +96.05% |
Concord Biotech is the fourth-largest holding among the five stocks, with a portfolio value of ₹3,575.8 crore. The group owns 25,199,240 shares, representing a 24.1% stake. Concord Biotech is an R&D-driven biopharma company focused on fermentation-based APIs and finished dosage formulations. The stock closed at ₹1,419, with a market capitalisation of ₹14,817 crore and a P/E ratio of 52.1. Its ROCE stands at 17.4%, while ROE is 12.6%.
Loading chart...
| Metric | Concord Biotech |
|---|---|
| Share price | ₹1,419 |
| 52-week high | ₹1,802 |
| 52-week low | ₹987 |
| Market cap | ₹14,817 crore |
| P/E | 52.1 |
| Book value | ₹193 |
| Dividend yield | 0.53% |
| ROCE | 17.4% |
| ROE | 12.6% |
| Portfolio holding | 24.1% |
| Holding value | ₹3,575.8 crore |
Concord Biotech gained 3.96% on August 10 and rose 11.50% over one month. It also gained 11.54% over six months, while the one-year return remained negative at 13%.
| Period | Return |
|---|---|
| 1 day | +3.96% |
| 5 days | -0.13% |
| 1 month | +11.50% |
| 6 months | +11.54% |
| 1 year | -13.00% |
| 5 years | +50.51% |
Fortis Healthcare is the fifth largest holding in this group, with 30,350,152 shares held by Rakesh Jhunjhunwala and Associates. The stake stands at 4.0%, while the holding value is ₹2,868.5 crore. Fortis operates hospitals, diagnostics and day-care healthcare facilities, with operations across India and selected international markets according to the supplied information. The stock closed at ₹945 and has a market capitalisation of ₹70,994 crore. Its P/E ratio is 66.6, while ROCE stands at 13.4% and ROE at 11.2%.
Loading chart...
| Metric | Fortis Healthcare |
|---|---|
| Share price | ₹945 |
| 52-week high | ₹1,105 |
| 52-week low | ₹767 |
| Market cap | ₹70,994 crore |
| P/E | 66.6 |
| Book value | ₹131 |
| Dividend yield | 0.11% |
| ROCE | 13.4% |
| ROE | 11.2% |
| Portfolio holding | 4.0% |
| Holding value | ₹2,868.5 crore |
Fortis Healthcare declined 1.05% on August 10, while its one-month return was negative 2.75%. The stock has gained 6.92% over one year and delivered a 296.21% return over five years.
| Period | Return |
|---|---|
| 1 day | -1.05% |
| 5 days | +0.02% |
| 1 month | -2.75% |
| 6 months | +6.04% |
| 1 year | +6.92% |
| 5 years | +296.21% |
The five holdings show a wide gap in returns across different time periods. Titan has delivered the strongest one-year performance among the five at 49.02%, while Fortis Healthcare has the highest five-year return at 296.21%. Metro Brands has been under pressure over the past year, while Inventurus Knowledge Solutions has also recorded negative five-year returns. Concord Biotech has gained over the past month and six months despite remaining below its level a year earlier.
| Stock | 1 day | 1 month | 6 months | 1 year | 5 years |
|---|---|---|---|---|---|
| Titan Company | +3.02% | +10.55% | +19.55% | +49.02% | +182.91% |
| Inventurus Knowledge Solutions | -0.51% | -8.55% | +1.87% | +6.51% | -11.83% |
| Metro Brands | -0.54% | -8.58% | -7.96% | -14.59% | +96.05% |
| Concord Biotech | +3.96% | +11.50% | +11.54% | -13.00% | +50.51% |
| Fortis Healthcare | -1.05% | -2.75% | +6.04% | +6.92% | +296.21% |
The June 2026 shareholding data shows limited movement in the five holdings covered above, with the reported stake unchanged for Titan, Inventurus Knowledge Solutions, Metro Brands, Concord Biotech and Fortis Healthcare. Elsewhere in the portfolio, Rakesh Jhunjhunwala and Associates trimmed its Star Health holding by 14.1% during the June 2026 quarter. The group also reduced its Canara Bank holding by 0.1% and marginally cut its Baazar Style Retail stake by 0.1%. Its holding in Raghav Productivity fell below the 1% reporting threshold during the quarter.
The five holdings have different valuation and return profiles. Titan trades at a P/E of 77.4, Metro Brands at 64.9, Fortis Healthcare at 66.6, Concord Biotech at 52.1 and Inventurus Knowledge Solutions at 38.9. The supplied data also shows relatively high ROE for Titan and Inventurus Knowledge Solutions, while Fortis Healthcare has delivered the strongest five-year stock return among the five. Investors tracking the portfolio should therefore look at each company's earnings, valuation and business performance separately instead of treating the portfolio as a single investment theme.
Rakesh Jhunjhunwala and Associates' portfolio remains spread across different parts of the Indian economy, with Titan and Inventurus Knowledge Solutions accounting for a large portion of the value among the five holdings analysed here. The latest share prices show strong long-term performance in Titan and Fortis Healthcare, while Metro Brands, Concord Biotech and Inventurus Knowledge Solutions have faced periods of weaker recent performance. Future movement in these stocks will depend on company earnings, valuation levels and business execution. Changes in the portfolio's shareholding should also be monitored, although a change in an investor's stake does not by itself indicate the future direction of a stock.
The five stocks covered are Titan Company, Inventurus Knowledge Solutions, Metro Brands, Concord Biotech and Fortis Healthcare. Together, the reported holding value of these five stocks is about ₹48,885 crore.
Titan Company is the largest holding among the five, with a reported holding value of ₹24,016.9 crore and a 5.3% stake.
Inventurus Knowledge Solutions has the highest reported holding percentage among these five stocks at 49.3%, followed by Concord Biotech at 24.1% and Metro Brands at 14.4%.
Fortis Healthcare has the highest five-year return among the five stocks, at 296.21%, based on the supplied stock performance data.
Titan Company has the highest one-year return among the five stocks at 49.02%.
Titan Company closed at ₹5,090 on August 10, 2026, according to the supplied data.
Inventurus Knowledge Solutions closed at ₹1,729 on August 10, 2026.
Metro Brands closed at ₹967 on August 10, 2026.
Concord Biotech closed at ₹1,419 on August 10, 2026.
Fortis Healthcare closed at ₹945 on August 10, 2026.
The supplied June 2026 data shows no change in the reported stakes of Titan Company, Inventurus Knowledge Solutions, Metro Brands, Concord Biotech and Fortis Healthcare. The group did, however, trim its Star Health holding by 14.1%, reduce Canara Bank by 0.1% and marginally reduce Baazar Style Retail by 0.1%.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
Petronet LNG's Q1FY27 EBITDA rose 26% as Nomura retained its Rs 345 target and Buy rating, with volume recovery expected from 4QFY27.
Indian media and entertainment sector stock jumps 8% after SAT grants interim relief in a SEBI case, clearing a path for a ₹3,143 crore promoter...
Aerospace and defence business sees a sharp Q1 FY27 revenue jump as acquisitions, global partnerships and major defence orders reshape its growth...
Tarsons Products shares surge 12% to a 52-week high as trading volumes rise, despite weak Q1 profit.
Passenger vehicle stock falls nearly 6% after Q1 profit drops 78.54% to ₹859 crore. Revenue rises 9%, while JLR headwinds weigh on earnings and...
